Phase 3 study of K-828-SP (Long-term study of sodium valproate in child patients with spinal muscular atrophy)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Sodium valproate (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kowa Pharmaceutical
- 27 Sep 2017 Planned End Date changed from 31 Mar 2018 to 30 Sep 2018.
- 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2016 New trial record